Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MedtronicBSP:MDTC34 +2.20%77 EV-to-EBITDA is 13.29 as of Aug. 12, 2026, which is 15% below its 10-year median of 15.56. GuruFocus rates BSP:MDTC34 with a GF Score™ of 77/100 and a GF Value™ of R$63.87 (Fairly Valued). The stock has 3 warning signs investors should review. Among 515 Medical Devices & Instruments companies, Medtronic ranks better than 53.59% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Medtronic's enterprise value is R$691,924 Mil.
Medtronic's EBITDA for the trailing twelve months (TTM) ended in Apr. 2026 was R$52,065 Mil. Therefore, Medtronic's EV-to-EBITDA for today is 13.29.
The historical rank and industry rank for Medtronic's EV-to-EBITDA or its related term are showing as below:
BSP:MDTC34'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 11.66 Med: 15.56 Max: 31.4
Current: 13.81
During the past 13 years, the highest EV-to-EBITDA of Medtronic was 31.40. The lowest was 11.66. And the median was 15.56.
BSP:MDTC34's EV-to-EBITDA is ranked better than 53.59% of 515
companies
in the Medical Devices & Instruments industry
Industry Median: 14.92
vs BSP:MDTC34: 13.81
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Medtronic's share price for today is R$57.95.
Medtronic's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$2.477.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Medtronic's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:MDTC34 vs SYK, BSX, EW: EV-to-EBITDA Comparison
For the Medical Devices subindustry, Medtronic's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medtronic EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medtronic's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Medtronic's EV-to-EBITDA falls into.
Medtronic's current Enterprise Value is R$691,924 Mil.
Medtronic's EBITDA for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$52,065 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medtronic (BSP:MDTC34) has a EV-to-EBITDA of 13.29 as of Aug. 12, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Medtronic. This is 15% below median its historical median of 15.56. Over the past decade, Medtronic's EV-to-EBITDA has ranged from 11.66 to 31.40. According to the industry distribution chart, Medtronic ranks #239 out of 515 companies in the Medical Devices & Instruments industry, placing it in the top 46.4%.
Is Medtronic's EV-to-EBITDA too high?
Medtronic's current EV-to-EBITDA of 13.29 is 15% below median its 10-year median of 15.56. Over the past 10 years, this metric has ranged from a low of 11.66 to a high of 31.40. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.92. Medtronic's value of 13.29 is 10.9% below this industry median. Based on the distribution chart, Medtronic ranks #239 out of 515 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Medtronic has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Medtronic's EV-to-EBITDA compare to SYK and BSX?
According to the Medical Devices & Instruments industry distribution chart, Medtronic ranks #239 out of 515 companies for EV-to-EBITDA. This puts Medtronic in the upper half of its industry. The industry median EV-to-EBITDA is 14.92. Medtronic's value of 13.29 is 10.9% below this benchmark. Historically, Medtronic's own EV-to-EBITDA has ranged from 11.66 to 31.40 over the past decade. While the company's 10-year median is 15.56 vs. the industry median of 14.92, Medtronic has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.92, based on 515 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medtronic's current EV-to-EBITDA of 13.29 is 10.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Medtronic. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medtronic's current EV-to-EBITDA is 13.29, which is 15% below median its own 10-year median of 15.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medtronic stock overvalued right now?
Based on GuruFocus' analysis, Medtronic (BSP:MDTC34) is currently considered Fairly Valued. The stock's GF Value™ is R$63.87, compared to a current price of R$57.95 — trading 9.3% below its estimated fair value. The current EV-to-EBITDA is 13.29, which is 15% below median its 10-year median of 15.56 and 10.9% below the Medical Devices & Instruments industry median of 14.92. Medtronic's overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Medtronic (BSP:MDTC34), the current EV-to-EBITDA is 13.29 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medtronic (BSP:MDTC34) Overvalued in 2026?
Based on GuruFocus' analysis, Medtronic stock appears to be undervalued.
The current stock price of R$57.95 is trading 9.3% below its estimated GF Value™ of R$63.87.
GuruFocus considers Medtronic to be Fairly Valued.
Key valuation signals for BSP:MDTC34:
EV-to-EBITDA: 13.29 (15% below median its 10-year median of 15.56)
GF Value™: R$63.87 vs. price of R$57.95 (9.3% below fair value)
Industry Position: 10.9% below the Medical Devices & Instruments median (#239 of 515)
No single metric tells the full story. See the BSP:MDTC34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, spinal fixation devices, neurovascular products, advanced energy, ablation laser therapy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.
77GF Score
Get the complete analysis for BSP:MDTC34
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:MDTC34 has been successfully added to your 
